Monday, November 14, 2022 3:57:58 PM
Blah,Blah,Blah,Blah
When you have a successful Phase 3 results that are a direct result of financing from NIH, it sure does effect NW Bio "commercializing". NIH loves it when funding money has been used on a successful Phase 3 trial, whether that is a COVID19 vaccine or as in this case, a cancer vaccine. Return on investment. Ands, just incase you somehow missing the the title of the Abstract she will be presenting this coming Sunday.
Funny thing, is the real "move" hasnt even happened yet. 16% is a pittance compared to what is going to happen here. Meanwhile, M2Play is spouting nonsense on issues and situations he.she clearly has no idea about. Keep going, I love it.
-Fireman
This has no effect on Nwbo commercializing.
When you have a successful Phase 3 results that are a direct result of financing from NIH, it sure does effect NW Bio "commercializing". NIH loves it when funding money has been used on a successful Phase 3 trial, whether that is a COVID19 vaccine or as in this case, a cancer vaccine. Return on investment. Ands, just incase you somehow missing the the title of the Abstract she will be presenting this coming Sunday.
Autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent glioblastoma: survival results from a phase 3 trial"
Funny thing, is the real "move" hasnt even happened yet. 16% is a pittance compared to what is going to happen here. Meanwhile, M2Play is spouting nonsense on issues and situations he.she clearly has no idea about. Keep going, I love it.
-Fireman
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
